COVID Booster in Pregnancy and Lactation

Last updated: November 24, 2025
Sponsor: Thomas Jefferson University
Overall Status: Completed

Phase

N/A

Condition

Covid-19

Breast Feeding

Treatment

Bivalent COVID-19 Booster

Clinical Study ID

NCT05543993
22F.452
  • Ages 13-55
  • Female
  • Accepts Healthy Volunteers

Study Summary

This is a prospective longitudinal cohort study to evaluate the impact of COVID-19 vaccination and booster on maternal and infant immunity against COVID-19 variants over time.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Singleton gestation

  • Received mRNA bivalent COVID-19 booster during 1) pregnancy or 2) breastfeeding

Exclusion

Exclusion Criteria:

  • Multifetal gestation

  • Unable to provide consent

Study Design

Total Participants: 150
Treatment Group(s): 1
Primary Treatment: Bivalent COVID-19 Booster
Phase:
Study Start date:
September 29, 2022
Estimated Completion Date:
June 10, 2024

Study Description

We will enroll 100 pregnant patients who have received COVID-19 mRNA booster as well as 100 breastfeeding patients who have received COVID-19 mRNA booster. Participants will be following longitudinally through 3 months post partum, or 3 months post enrollment for those in the breastfeeding cohort. Maternal blood will be collected, as will cordblood at delivery, breastmilk, and infant samples.

Connect with a study center

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania 19107
    United States

    Site Not Available

  • Thomas Jefferson University Hospital

    Philadelphia 4560349, Pennsylvania 6254927 19107
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.